Double‐blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy

  title={Double‐blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy},
  author={Yadollah Harati and Catherine Gooch and M. Swenson and Shani Edelman and D Greene and Philip Raskin and Peter D. Donofrio and David R. Cornblath and Rajesh C. Sachdeo and Cynthia O. Siu and Marc Kamin},
  pages={1842 - 1846}
Objective The objective of this study was to evaluate the efficacy and safety of tramadol in treating the pain of diabetic neuropathy. Background The pain of diabetic neuropathy is a major cause of morbidity among these patients and treatment, as with other small-fiber neuropathies, is often unsatisfactory. Tramadol is a centrally acting analgesic for use in treating moderate to moderately severe pain. Methods This multicenter, outpatient, randomized, double-blind, placebo-controlled, parallel… 

Figures and Tables from this paper

Tramadol in Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-blind, Placebo-controlled Trial
Tramadol might be tried for neuropathic pain after SCI after the use of gabapentin/pregabalin, and tricyclic antidepressants have been found to be insufficient.
Zonisamide in the treatment of painful diabetic neuropathy: a randomized, double-blind, placebo-controlled pilot study.
Pain scores on both the visual analog scale and the Likert scale decreased more for the zonisamide group compared with the placebo group, regardless of whether the comparison was made for the intent-to-treat population, the population that entered the maintenance phase, or the completer population, but differences did not reach statistical significance.
Controlled-release oxycodone for pain in diabetic neuropathy
In this 6-week trial, CR oxycodone was effective for the treatment of moderate to severe pain due to diabetic neuropathy and the most common adverse events were opioid related.
Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial
Compared with placebo, tapentadol ER 100–250 mg bid provided a statistically significant difference in the maintenance of a clinically important improvement in pain12 and was well-tolerated by patients with painful DPN.
Analgesic Efficacy and Safety of Tramadol/ Acetaminophen Combination Tablets (Ultracet®) in Treatment of Chronic Low Back Pain: A Multicente , Outpatient, Randomized, Double Blind, Placebo Controlled Trial
Tramadol 37.5 mg/APAP 325 mg combination tablets show efficacy in pain reduction, in measures of physical functioning and quality of life, and in overall medication assessments, with a tolerability profile comparable with other opioids used for the treatment of chronic LBP.
A randomized, double-blind, crossover comparison of the efficacy and safety of oral controlled-release tramadol and placebo in patients with painful osteoarthritis.
CR tramadol is effective for the management of painful osteoarthritis and 86.5% of patients reported at least moderate benefit from CR tramadols during long-term treatment.
Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy
Tramadol/APAP was more effective than placebo and was well tolerated in the management of painful DPN and was associated with significantly greater improvement than placebo.


Clinical investigation on the development of dependence during oral therapy with tramadol.
The outcome of the study suggests that tramadol under the conditions described does not induce dependence.
Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.
Desipramine relieves pain caused by diabetic neuropathy with efficacy similar to that of amitriptyline, offering an alternative for patients unable to tolerate the latter and blockade of norepinephrine reuptake is likely to mediate the analgesic effect of these antidepressant drugs in diabetic Neuropathy.
Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy.
Further studies are necessary to evaluate the significance of aldose reductase-inhibitor properties of nonsteroidal anti-inflammatory drugs and to select the "best" one of these drugs for the treatment of diabetic neuropathy.
Tegretol in the treatment of diabetic neuropathy.
  • T. D. Wilton
  • Medicine
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
  • 1974
Patients suffering from peripheral neuropathy caused by diabetes mellitus were admitted to a double-blind trial comparing the efficacy of Tegretol (carbamazepine) and placebo and significant relief of pain was obtained.
Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood
It is concluded that amitriptyline relieves pain in diabetic neuropathy; this effect is independent of mood elevation.
Diabetic peripheral neuropathy: nerve conduction studies before, during and after carbamazepine therapy.
It was concluded that carbamazepine is a dependable drug for the treatment of symptomatic diabetic sensory polyneuropathy.
Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic.
The results suggest that tramadol-induced antinociception is mediated by opioid (mu) and nonopioid (inhibition of monoamine uptake) mechanisms, and is consistent with the clinical experience of a wide separation between analgesia and typical opioid side effects.
Diabetic peripheral neuropathies.
  • Y. Harati
  • Medicine, Biology
    Annals of internal medicine
  • 1987
The balance of evidence indicates that attainment and maintenance of normal blood glucose remains the cornerstone of treatment of diabetes and diabetic neuropathies and there is no convincing evidence that any of the treatments devised to correct the metabolic derangements in nerve are of sufficient value or safety to be recommended for routine use.
Diabetes Mellitus and Its Degenerative Complications: A Prospective Study of 4,400 Patients Observed Between 1947 and 1973
This article was originally published in French in Diabete et Metabolisme (vol. 3: 97–107, 173–182, 245–256; 1977) and is being translated by Marjorie Levin of Miami, Florida.
Measuring Functioning and Well-Being: The Medical Outcomes Study Approach
This book provides a set of ready-to-use generic measures that are applicable to all adults, including those well and chronically ill, as well as a methodological guide to collecting health data and constructing health measures.